Ideaya Biosciences received FDA IND clearance to initiate a Phase I study of IDE‑034, a bispecific B7H3/PTK7 TOP1 antibody‑drug conjugate targeting solid tumors. The clearance opens human testing for a payload‑delivery ADC aimed at tumors expressing the dual antigens. Separately, Generate:Biomedicines announced plans to start two Phase III studies for its TSLP antibody, advancing its AI‑augmented discovery program into late‑stage development. The move marks a key clinical inflection point for AI‑driven biotech platforms. Both regulatory steps underscore continued momentum in translational programs where novel modalities and AI‑discovered candidates are moving from discovery into registrational testing.